A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

OBJECTIVES The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus maraviroc, both with tenofovir disoproxil/emtricitabine as the backbone. METHODS We conducted a prospective, open, randomized clinical trial. Individuals attending the emergency room because of potential sexual exposure to HIV and who met criteria for receiving PEP were randomized to one of two groups: tenofovir disoproxil/emtricitabine (245/200 mg) once daily plus either ritonavir-boosted lopinavir (400/100 mg) or maraviroc (300 mg) twice daily. Five follow-up visits were scheduled for days 1, 10, 28, 90 and 180. The primary endpoint was PEP non-completion at day 28. Secondary endpoints were adherence, adverse events and rate of seroconversions. This study was registered in ClinicalTrials.gov: NCT01533272. RESULTS One-hundred-and-seventeen individuals were randomized to receive ritonavir-boosted lopinavir and 120 to maraviroc (n = 237). PEP non-completion at day 28 was 38% (n = 89), with significant differences between arms [ritonavir-boosted lopinavir 44% (n = 51) versus maraviroc 32% (n = 38), P = 0.05]. We performed a modified ITT analysis including only those patients who attended on day 1 (n = 182). PEP non-completion in this subgroup was also significantly higher in the ritonavir-boosted lopinavir arm (27% versus 13%, P = 0.004). The proportion of patients with low adherence was similar between arms (52% versus 47%, P = 0.56). Adverse events were reported by 111 patients and were significantly more common in the ritonavir-boosted lopinavir arm (72% versus 51%, P = 0.003). No seroconversions were observed during the study. CONCLUSIONS PEP non-completion and adverse events were both significantly higher in patients allocated to ritonavir-boosted lopinavir. These data suggest that maraviroc is a well-tolerated antiretroviral that can be used in this setting.

[1]  Felipe García,et al.  A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. , 2016, The Journal of antimicrobial chemotherapy.

[2]  A. McNulty,et al.  Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  N. Ford,et al.  The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  N. Ford,et al.  Formulating the Future Research Agenda for Postexposure Prophylaxis for HIV: Methodological Challenges and Potential Approaches. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  N. Ford,et al.  Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis , 2014, AIDS.

[6]  K. Mayer,et al.  Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. , 2014, AIDS.

[7]  I. Bogoch,et al.  Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  N. Ford,et al.  Systematic review and meta‐analysis: Patient and programme impact of fixed‐dose combination antiretroviral therapy , 2014, Tropical medicine & international health : TM & IH.

[9]  David K. Henderson,et al.  Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis , 2013, Infection Control & Hospital Epidemiology.

[10]  C. Reback,et al.  High-Risk Sexual Behavior Is Associated with Postexposure Prophylaxis Nonadherence among Men Who Have Sex with Men Enrolled in a Combination Prevention Intervention , 2013, Journal of sexually transmitted diseases.

[11]  John P. Moore,et al.  Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. , 2013, The Journal of antimicrobial chemotherapy.

[12]  M. Mimiaga,et al.  Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV: Safety, Tolerability, and Adherence , 2012, Journal of acquired immune deficiency syndromes.

[13]  N. Ford,et al.  Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis , 2012, Sexually Transmitted Infections.

[14]  B. Clotet,et al.  Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine , 2012, Antiviral therapy.

[15]  N. Beeching,et al.  HIV post-exposure prophylaxis programmes in the developed and developing world: can we learn from each other? , 2011, International journal of STD & AIDS.

[16]  Till Bärnighausen,et al.  Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. , 2011, The Lancet. Infectious diseases.

[17]  Myron S. Cohen,et al.  Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. , 2011, The Journal of infectious diseases.

[18]  M. Cavassini,et al.  Nonoccupational HIV post‐exposure prophylaxis: a 10‐year retrospective analysis , 2010, HIV medicine.

[19]  B. Christian,et al.  Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation , 2010, AIDS.

[20]  B. Damle,et al.  Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.

[21]  M. Mimiaga,et al.  Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center , 2008, Journal of acquired immune deficiency syndromes.

[22]  J. Delfraissy,et al.  Post‐exposure prophylaxis with a maraviroc‐containing regimen after occupational exposure to a multi‐resistant HIV‐infected source person , 2008, Journal of medical virology.

[23]  Dongwen Wang,et al.  Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus , 2007, Infection Control & Hospital Epidemiology.

[24]  C. Duncombe,et al.  Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children adolescents and adults. Recommendations for a public health approach. , 2006 .

[25]  J. Kahn,et al.  Seroconversion following nonoccupational postexposure prophylaxis against HIV. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  L. Grohskopf,et al.  Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[27]  B. Christian,et al.  Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. Casabona,et al.  Recomendaciones para la profilaxis postexposición no ocupacional al VIH , 2002 .

[29]  J. Casado,et al.  Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study , 2002, AIDS.

[30]  C. Rabaud,et al.  Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  I. Escobar,et al.  Study of the Validity of a Questionnaire to Assess the Adherence to Therapy in Patients Infected by HIV , 2001, HIV clinical trials.

[32]  E. Ricci,et al.  Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected Patients , 1999, Antiviral therapy.

[33]  R. Paredes,et al.  Monitoring adherence to HIV therapy. , 1999, Archives of internal medicine.

[34]  J. Lifson,et al.  Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of Treatment , 1998, Journal of Virology.

[35]  D. Cardo,et al.  Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994. , 1995, MMWR. Morbidity and mortality weekly report.

[36]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.